Matinas BioPharma Inc. (NASDAQ: (MTNB) stock gained by 6.36% at the last close while the MTNB stock price surges by 2.56% in the pre-market trading session. Matinas BioPharma is a pharmaceutical business that uses its paradigm-shifting lipid nanocrystal (LNC) delivery platform to improve the intracellular delivery of important medications.
MTNB stock’ Update
Kathryn Penkus Corzo has been nominated by Matinas BioPharma to run for election to the Company’s Board of Directors at its 2021 Annual Meeting of Stockholders, which will take place on November 1, 2021. Ms. Corzo is a partner at Takeda Ventures, Inc., and was previously the Head of Oncology Cell Therapy Development at Takeda Pharmaceuticals, a worldwide, values-based, R&D-driven biopharmaceutical company based in Japan. Ms. Corzo works at Takeda’s research and development centre in Cambridge, Massachusetts.
About this, Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors, and Chair of the Nominating and Governance Committee said that, they are thrilled to announce Kathryn’s appointment to their Board of Directors. Kathryn is a well-known biotechnology executive with a long track record of success in medication development. As they broaden the use of their LNC platform delivery technology, her leadership roles and development accomplishments with big pharmaceutical firms will be tremendously useful to the Company.
Furthermore,
Patrick LePore will not seek re-election to the Board of Directors at the Company’s Annual Meeting of Stockholders on November 1, 2021, according to the company.
Jerome D. Jabbour, Chief Executive Officer of Matinas acknowledged Pat LePore for his dedication to the Company on behalf of the Board of Directors and Matinas. His leadership, experience, and vision have been important in the company’s efforts over the last three years to work for the best interests of all Matinas stakeholders. Also, he wished him great success for the future.
Patrick LePore commented that,
He is thankful to Jerry and Herb, as well as the whole Board of Directors, for allowing me to participate as Vice Chairman of the Company. Matinas is incredibly well-positioned for the future, with good EnACT data just announced and several additional major clinical and strategic objectives coming up in the next quarters.
